| The
group commissioned Bridgehead Consulting to provide an independent
assessment of the technology and to establish the commercial
opportunity within the biotech and pharma sectors. Bridgehead
Consulting also advised the group on their future intellectual
property strategy and built a development and commercialisation
strategy to define the company's future direction.
The objectives for the client
-
To provide the university team with
an assessment of the current status of the radio and fluorescent-labelled
ligand markets from both the supplier and user perspective.
-
To gain feedback from the market on:
-
fluorescent ligands with the qualities
of those under development by the group
-
interest in the ability to carry
out screening on single cells
-
interest in access to the expertise
available within the group for development of bespoke
ligands
-
potential market entry barriers.
The programme of work
The programme of work comprised iterative
desk research, internal interviews with the university group
and external interviews with high throughput screening and
assay development groups within the pharmaceutical and biotechnology
industry, covering:
-
a review and analysis of the fluorescent
ligand technology of the university group
-
an analysis of the structure, size,
trends, factors impacting on the market, key market segments
and key players of the labelled ligand market
-
assessment of the strengths and weaknesses
of existing and developing competitive technologies, and
the level of interest in the company's services and technologies
-
a review of the IP situation.
Bridgehead Consulting then generated a series
of business models and held a strategic workshop to discuss
the future business and development strategy of the proposed
spin-out company. |
|
The
deliverables to the client |
|
Bridgehead Consulting delivered a comprehensive
report addressing the company's stated objectives. This
allowed conclusions to be drawn on the size and nature
of the potential opportunity for this fluorescent-labelled
ligand technology and the appropriateness of the various
business models considered. |
| |
The
project achievements |
-
The client received requests for
confidential discussion of its technology from four
major pharmaceutical companies, two assay development
companies and a major reagent and consumables supplier.
-
The client implemented a comprehensive
and focused intellectual property plan.
-
It enabled the client to make
clear decisions on the future development route
and a business model.
Added value
Through its extensive high-level contacts
within large pharmaceutical and biotechnology, Bridgehead
Consulting was able to generate interest in the client's
technology. This has progressed to confidential discussions
with a range of potentially influential collaborator/customer
companies. |
| |
|
PDF Version